补肺活血胶囊联合乌美溴铵维兰特罗治疗稳定期COPD的疗效观察

Observation on the curative effect of Bufei Huoxue Capsules combined with Umeclidinium Bromide and Vilanterol Trifenatate in the treatment of stable COPD

目的探讨补肺活血胶囊联合乌美溴铵维兰特罗治疗稳定期慢性阻塞性肺疾病(COPD)的效果。方法选取2021年6月至2022年11月江西省胸科医院门诊收治的60例稳定期COPD患者为研究对象,按照随机数字表法分为对照组(30例)和研究组(30例)。对照组采用乌美溴铵维兰特罗治疗,研究组采用补肺活血胶囊联合乌美溴铵维兰特罗治疗,比较两组患者持续治疗3个月后的肺功能、运动耐量、生活质量及症状急性加重次数。结果治疗前,两组患者肺总量(TLC)、第1秒用力呼气量(FEV1)、用力肺活量(FVC)、一秒率(FEV1%)水平比较,差异无统计学意义(P>0.05);治疗后,研究组的FEV1、FVC、FEV1%水平高于对照组,TLC水平低于对照组,差异有统计学意义(P<0.05)。治疗前,两组的6分钟步行距离(6MWT)、圣乔治呼吸问卷(SGRQ)、COPD患者自我评估测试问卷(CAT)比较,差异无统计学意义(P>0.05);治疗后,研究组的6MWT长于对照组,SGRQ评分、CAT评分低于对照组,差异有统计学意义(P<0.05)。研究组的咳嗽、咳痰、胸闷、气喘急性加重次数均少于对照组,差异有统计学意义(P<0.05)。结论针对稳定期COPD患者,采用补肺活血胶囊联合乌美溴铵维兰特罗治疗可以明显改善患者病症,减少急性加重次数,改善肺功能、生活质量,提高患者运动能力,可推广应用。

Objective To investigate the effect of Bufei Huoxue Capsules combined with Umeclidinium Bromide and Vilanterol Trifenatate on stable chronic obstructive pulmonary disease(COPD).Methods Sixty patients with stable COPD admitted to the outpatient department of Jiangxi Chest Hospital from June 2021 to November 2022 were selected as the study objects,and were divided into control group(30 cases)and study group(30 cases)according to random number table method.The control group was treated with Umeclidinium Bromide and Vilanterol Trifenatate,while the study group was treated with Bufei Huoxue Capsules combined with Umeclidinium Bromide and Vilanterol Trifenatate.Lung function,exercise tolerance,quality of life and acute exacerbation of symptoms were compared between the two groups after continuous treatment for 3 months.Results Before treatment,there were no statistical significances in total lung volume(TLC),forced expiratory volume at 1 second(FEV1),forced vital capacity(FVC)and one-second rate(FEV1%)between two groups(P>0.05).After treatment,the levels of FEV1,FVC and FEV1%in the study group were higher than those in the control group,and the level of TLC was lower than that in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in 6-minute walking distance(6MWT),St.George's breathing questionnaire(SGRQ),COPD self-assessment questionnaire(CAT)between control group and study group(P>0.05).After treatment,the 6MWT of the study group was longer than that of the control group,but the SGRQ score and CAT score were lower than those of the control group,the differences were statistically significant(P<0.05).The acute aggravation times of cough,expectoration,chest tightness and asthma in the study group were less than those in the control group,and the differences were statistically significant(P<0.05).Conclusion For stable COPD patients,the treatment of Bufei Huoxue Capsules combined with Umeclidinium Bromide and Vilanterol Trifenatate can significantly improve the symptoms of patients,reduce the number of acute exacerbations,improve lung function,quality of life,improve the exercise ability of patients,and can be widely used.